These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8817678)

  • 1. Pharmacokinetics and bioavailability of rhIGF-I/IGFBP-3 in the rat and monkey.
    Adams S; Moore J; Chu S; Bagi C; DeLeon L; Liu C; Schmidt D; Sommer A
    Prog Growth Factor Res; 1995; 6(2-4):347-56. PubMed ID: 8817678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
    Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-II and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus.
    Cheetham TD; Holly JM; Baxter RC; Meadows K; Jones J; Taylor AM; Dunger DB
    J Endocrinol; 1998 Apr; 157(1):81-7. PubMed ID: 9614361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of recombinant human insulin-like growth factor-I in diabetic rats.
    Higaki K; Matsumoto Y; Fujimoto R; Kurosaki Y; Kimura T
    Drug Metab Dispos; 1997 Nov; 25(11):1324-7. PubMed ID: 9351911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans.
    Lieberman SA; Bukar J; Chen SA; Celniker AC; Compton PG; Cook J; Albu J; Perlman AJ; Hoffman AR
    J Clin Endocrinol Metab; 1992 Jul; 75(1):30-6. PubMed ID: 1377706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats.
    Fielder PJ; Mortensen DL; Mallet P; Carlsson B; Baxter RC; Clark RG
    Endocrinology; 1996 May; 137(5):1913-20. PubMed ID: 8612531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
    Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
    Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic considerations with recombinant human insulin-like growth factor-I in children.
    Ferry RJ; Cohen P; Levitt Katz LE
    Horm Res; 2005; 63(5):220-7. PubMed ID: 15886488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
    Holt RI; Guha N; Böhning W; Bartlett C; Cowan DA; Sönksen PH; Böhning D
    Drug Test Anal; 2017 Jan; 9(1):30-37. PubMed ID: 26888146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purified rat acid-labile subunit and recombinant human insulin-like growth factor (IGF)-binding protein-3 can form a 150-kilodalton binary complex in vitro in the absence of IGFs.
    Lee CY; Rechler MM
    Endocrinology; 1995 Nov; 136(11):4982-9. PubMed ID: 7588232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of insulin-like growth factor-binding protein-3 ternary complex formation in pregnancy.
    Lewitt MS; Scott FP; Clarke NM; Wu T; Sinosich MJ; Baxter RC
    J Endocrinol; 1998 Nov; 159(2):265-74. PubMed ID: 9795367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of GH therapy on the immunoreactive forms and distribution of IGFBP-3, IGF-I, the acid-labile subunit, and growth rate in GH-deficient children.
    Mandel SH; Moreland E; Rosenfeld RG; Gargosky SE
    Endocrine; 1997 Dec; 7(3):351-60. PubMed ID: 9657073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developmental changes in pharmacokinetics of recombinant human insulin-like growth factor-I in rats.
    Higaki K; Matsumoto Y; Fujimoto R; Kurosaki Y; Kimura T
    Res Commun Mol Pathol Pharmacol; 1997 Aug; 97(2):115-24. PubMed ID: 9344224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.
    Carroll PV; Umpleby M; Alexander EL; Egel VA; Callison KV; Sönksen PH; Russell-Jones DL
    Clin Endocrinol (Oxf); 1998 Dec; 49(6):739-46. PubMed ID: 10209561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of growth hormone (GH), but not insulin-like growth factor-I (IGF-I), by continuous infusion can induce the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats.
    Gargosky SE; Tapanainen P; Rosenfeld RG
    Endocrinology; 1994 May; 134(5):2267-76. PubMed ID: 7512499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased ternary complex formation and predominance of a 29 kDa IGFBP-3 fragment in human fetal serum.
    Bang P; Stangenberg M; Westgren M; Rosenfeld RG
    Growth Regul; 1994 Jun; 4(2):68-76. PubMed ID: 7524886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
    Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of recombinant human insulin-like growth factor (rhIGF)-1 and rhIGF-1/IGF binding protein-3 administration on rat osteopenia induced by ovariectomy with concomitant bilateral sciatic neurectomy.
    Narusawa K; Nakamura T; Suzuki K; Matsuoka Y; Lee LJ; Tanaka H; Seino Y
    J Bone Miner Res; 1995 Dec; 10(12):1853-64. PubMed ID: 8619365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of mecasermin rinfabate.
    Kemp SF; Fowlkes JL; Thrailkill KM
    Expert Opin Biol Ther; 2006 May; 6(5):533-8. PubMed ID: 16610982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.